| 1 |
34465864 | PHF6 and JAK3 mutations cooperate to drive T-cell acute lymphoblastic leukemia progression. | 2022 Feb |
2 |
| 2 |
33814980 | Mucosal Epithelial Jak Kinases in Health and Diseases. | 2021 |
2 |
| 3 |
34274356 | The JAK1/2 inhibitor baricitinib suppresses eosinophil effector function and restricts allergen-induced airway eosinophilia. | 2021 Oct |
2 |
| 4 |
32639993 | Kinome capture sequencing of high-grade serous ovarian carcinoma reveals novel mutations in the JAK3 gene. | 2020 |
2 |
| 5 |
30993508 | Preformulation and Evaluation of Tofacitinib as a Therapeutic Treatment for Asthma. | 2019 Apr 16 |
1 |
| 6 |
28852199 | Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia. | 2018 Mar |
1 |
| 7 |
29986854 | Partial trisomy 21 contributes to T-cell malignancies induced by JAK3-activating mutations in murine models. | 2018 Jul 10 |
2 |
| 8 |
27745702 | IL-4/IL-13-mediated polarization of renal macrophages/dendritic cells to an M2a phenotype is essential for recovery from acute kidney injury. | 2017 Feb |
1 |
| 9 |
28284718 | Novel JAK3-Activating Mutations in Extranodal NK/T-Cell Lymphoma, Nasal Type. | 2017 May |
2 |
| 10 |
28884378 | Efficacy of topical tofacitinib in promoting hair growth in non-scarring alopecia: possible mechanism via VEGF induction. | 2017 Nov |
2 |
| 11 |
27278657 | JAK3-STAT pathway blocking benefits in experimental lupus nephritis. | 2016 Jun 8 |
1 |
| 12 |
27732937 | Tofacitinib induces G1 cell-cycle arrest and inhibits tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells. | 2016 Nov 22 |
1 |
| 13 |
29046866 | Transforming Mutations of Jak3 (A573V and M511I) Show Differential Sensitivity to Selective Jak3 Inhibitors. | 2016 |
2 |
| 14 |
26164790 | Aggression behaviour induced by oral administration of the Janus-kinase inhibitor tofacitinib, but not oclacitinib, under stressful conditions. | 2015 Oct 5 |
1 |
| 15 |
23689514 | JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma. | 2014 Feb |
1 |
| 16 |
25193870 | JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. | 2014 Nov 13 |
1 |
| 17 |
24565406 | JAK3 inhibition: what potential for the future? | 2013 Nov 20 |
1 |
| 18 |
22252297 | Low dose CP-690,550 (tofacitinib), a pan-JAK inhibitor, accelerates the onset of experimental autoimmune encephalomyelitis by potentiating Th17 differentiation. | 2012 Feb 10 |
2 |
| 19 |
21393628 | Development of a high-throughput cell-based reporter assay for screening of JAK3 inhibitors. | 2011 Apr |
1 |
| 20 |
18094329 | The specificity of JAK3 kinase inhibitors. | 2008 Feb 15 |
1 |
| 21 |
18242596 | The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia. | 2008 Mar 17 |
2 |
| 22 |
14678034 | The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models. | 2004 Jan |
2 |
| 23 |
14593182 | Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. | 2003 Oct 31 |
1 |